B
rain metastases from systemic cancers are by far the most common cause of malignant central nervous system (CNS) SRS FOR METASTATIC BRAIN TUMORS to 7 mo from the time of their diagnosis; however, the last 2 decades have seen significant advances in diagnosis, prognosis, and treatment of patients with brain metastases. 1 There has remained considerable debate regarding the relative benefits in terms of survival, cancer control, and preservation of function and quality of life using stereotactic radiosurgery (SRS) or whole-brain radiotherapy (WBRT) in this population. This review assesses evidence pertaining to the use of SRS for metastatic brain tumors. No class I evidence was available in this review to establish whether SRS is recommended over other treatment options, alone or in combination, for adults with brain metastases. Prior major trials addressing this question usually included mixed populations of adult patients with different histologies that were stratified based on the previously described recursive partitioning analysis prognostic factors of age, number of metastases, and functional status. 2 Most of these trials only address WBRT or SRS as solitary interventions at a single time point, under the assumption that prior benefits of surgical interventions were independent and that subsequent treatments had no influence on these outcomes.
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METHODS
The following electronic databases were searched for the period of January 1, 1990 through December 31, 2015: PubMed, Embase, and Cochrane Central. The searches extended prior to the end date of the previously published guideline to account for the significant change in the questions related to SRS in this new guideline. An additional bibliography search of these candidate papers was also undertaken.
The citations were screened for pertinence to the topic at hand. The full texts of the selected manuscripts were reviewed, and predetermined inclusion and exclusion criteria were used to determine those to be used as evidence for this guideline. The selected articles were assessed for bias and classified according to criteria for evidence on therapeutic efficacy as detailed in the Joint Guidelines Committee Guideline Developmental Methodology (https://www.cns.org/guidelines/guideline-procedures-policies/guidelinedevelopment-methodology).
RESULTS
The search yielded 1780 unique articles. After reviewing the titles and abstracts, the authors excluded 997 articles based on the predetermined criteria (pediatric patients, less than 10 patients, etc). Also articles that did not directly address clinical outcomes of stereotactic radiosurgery for brain metastases or relevant prognostic information for patients with brain metastases that impacted interpretation of prior studies were excluded. This left us with 783 articles. Of these, 31 studies met the defined criteria for inclusion. The summary of resultant recommendations is as follows:
• SRS is a valid option compared to surgical resection in solitary metastases when surgical risks are high, and tumor volume and location are acceptable for employment of SRS.
• SRS alone is preferred to WBRT + SRS for most patients due to increased cognitive consequences with WBRT + SRS, without an improvement in other patient-relevant outcomes.
• SRS should be compared to WBRT on an individual patient basis using total tumor volume, disease-specific Graded Prognostic Assessment (GPA) and tumor histology and molecular status, as well as other factors, in deciding between the 2.
• SRS is a valid adjunctive therapy option to supportive palliative care and can improve patient symptoms and quality of life.
DISCUSSION
No available class I evidence exists to establish whether SRS should be preferred over surgical resection, alone or in combination. A single class III study examined the addition of WBRT versus observation after either nonrandomized surgical resection or SRS for 1 to 3 brain metastases and found no impact on functional independence based on the initial SRS versus resection. 5 Stereotactic radiosurgery or WBRT alone should be favored over WBRT + SRS for most patients, suggesting a detrimental effect of the combination on cognitive function and quality of life. 6 Prior class III evidence had suggested a possible improvement in median overall survival (mOS) for SRS + WBRT and other studies had reported improvements in intracranial recurrence, which is a less relevant clinical outcome than measures like mOS, functional independence, quality of life, and rigorously tested cognitive function.
Based on class III evidence, after open surgical resection of a solitary brain metastasis, SRS should be considered to decrease local recurrence rates depending on the presence of residual tumor, radiation risk of adjacent structures, and sensitivity to radiation versus systemic therapeutic options in the CNS based on molecular histology. 7, 8 No higher class studies have compared whether SRS should be used instead of WBRT after resection, but class III evidence from retrospective studies suggests a higher intracranial recurrence rate after SRS versus WBRT without a notable difference in OS. 9 Class III evidence supports the statement that patients with solitary brain metastasis can mostly be treated with SRS with equivalent or possibly improved outcomes and side effects compared to WBRT. [10] [11] [12] [13] [14] [15] It should be again noted that tumor size, total volume, and location may not always make SRS feasible.
Class III evidence suggests that stereotactic radiosurgery should be compared with WBRT for patients with 2 to 4 brain metastases (and possibly more), depending on total tumor volume, diagnosis-specific GPA, and patient-specific molecular histology and radiosensitivity, status of systemic disease and systemic therapeutic options, and consideration of the possibility of occult or impending diffuse leptomeningeal involvement. [16] [17] [18] [19] Several class III studies have addressed the use of SRS alone in patients with > 4 brain metastases and confirmed that OS is not different for patients with >4 brain metastases compared with 1 or 2 to 4 metastases when total tumor volume was <13 cc, and no single metastasis was >3 cc in volume.
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